Deep Learning Radiomics Model for Predicting Post-cystectomy Outcome in Muscle Invasive Bladder Cancer

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorFirst Affiliated Hospital of Chongqing Medical University

About this trial

Muscle invasive bladder cancer (MIBC) has a poor prognosis even after radical cystectomy. Postoperative survival stratification based on radiomics and deep learning may be useful for treatment decisions to improve prognosis. This study was aimed to develop and validate a deep learning radiomics model based on preoperative enhanced CT to predict postoperative survival in MIBC.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

patients with pathologically confirmed MIBC after radical cystectomy;

contrast-CT scan less than two weeks before surgery;

complete CT image data and clinical data.

Disqualifiers

patients who received neoadjuvant therapy;

non-urothelial carcinoma;

poor quality of CT images;

incomplete clinical and follow-up data.

Trial population

patients with pathologically confirmed MIBC who underwent radical cystectomy

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • develop and validate a deep learning radiomics model based on preoperative enhanced CT image

    Other intervention

    develop and validate a deep learning radiomics model based on preoperative enhanced CT to predict postoperative survival in MIBC

Treatment groups

500 Participants
are divided into 1 treatment group
Group A: MIBC1 intervention

Trial outcomes

Primary outcomes

1

Overall survival(OS)

the time from the date of surgery to death from any cause or the date of last contact (censored observation) at the date of data cut-off.

Time frame
up to 10 years
2

Recurrence free survival(RFS)

the time from the date of surgery to the date of first documented disease recurrence. Patients without recurrence at the time of analysis will be censored.

Time frame
up to 10 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.